New Breakthrough Therapy for Metastatic Melanoma Receives FDA Approval

A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center is now available for patients with advanced melanoma. It’s called TIL, short for tumor-infiltrating lymphocyte therapy. The one-time T-cell therapy infusion uses a patient’s own immune cells to fight their cancer.